MEDP Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 0.06%, SMA50 -0.41%, SMA200 35.06%). The stock’s 14-day RSI is 51.64 (neutral), while the ATR of 15.35 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -8.74% below its high and over 128.57% above its low. Average 10-day trading volume of 254.65 thousand shares is below the 3-month average of 287.19 thousand, indicating normal recent market interest.

Medpace Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $523.00. This means the shares are trading above this model’s fair value.

Medpace Holdings, Inc. (NASDAQ:MEDP) closed at $569.70 USD, losing -$1.83 (-0.32%) from the previous close of $571.53. The stock is currently mid-range between its 52-week high and low $250.05 and $626.25. With a market capitalization of about $16.05 billion, Medpace Holdings, Inc. is classified as a large-cap and shows higher-than-market volatility (beta ~1.43). Key stats such as the average daily volume over the past year has been around 298.19 thousand shares, volume is running light vs its 52-week average. Headquartered in Cincinnati, OH, Medpace Holdings, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO August James Troendle, the company employs approximately 5,900 people and listed since August 11, 2016. Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.

Medpace Holdings, Inc. generated EPS of $14.30 over the past year. Five-year average earnings growth is 36.5%. Wall Street analysts project EPS growth of 13.92% annually over the next five years. The latest quarter delivered EPS of $3.86. The next quarter is forecast at $4.18. Next year's EPS is expected at $15.94. Analyst sentiment is neutral. Analyst rating data shows there are 4 Strong Buy ratings, 0 Buy ratings, 11 Hold ratings, 3 Sell rating and 3 Strong Sell ratings. Price targets range from $655.00 to $300.00. The high target offers 14.6% upside. The low target suggests -47.51% downside. The mean target is $443.71. This offers -22.36% upside. Medpace Holdings, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 22, 2025, missed forecasts by 10.29%. The prior quarter beat by 4.03%. Over the last six quarters, Apple has recorded several small beats. These include 9.13% in July 22, 2024.

Medpace Holdings, Inc. has 28.09 million shares outstanding. The public float is 22.22 million shares, elevated short interest at 11.27% of float. This equals 2.50 million shares. The short ratio is 3.6 days. Institutional investors hold 122.04% of the float. Insiders own 20.7%. Medpace Investors, LLC holds 4.73 million shares, Troendle August J. has 646.18 thousand shares and BURWIG SUSAN E has 27.50 thousand shares. Over the past six months, insider transactions show net selling. They sold 556.09 thousand shares across 35 transactions.

Medpace Holdings, Inc. trades at a P/E ratio of 38.43, slightly above the S&P 500 average, with a price-to-sales ratio of 6.85 and a price-to-book ratio of 56.67 reflecting a rich premium to book value. The P/FCF stands at 22.95, also above market averages. Compared to sector medians, Medpace Holdings, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Medpace Holdings, Inc. (NASDAQ:MEDP) shares are up 72.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Medpace Holdings, Inc. trading at a premium to the broader market with a P/E of 38.43. Analyst sentiment is cautious, with the majority of ratings in Underweight territory and a mean price target of $358.86, suggesting -37.21% downside. Our AI forecast model points to short-term weakness (-2.85% over two weeks), a medium-term fall (-13.32% over three months), and a longer-term gain (14.11% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Medpace Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.85%, with price expected at $555.25 by January 05, 2026, within a range of $541.72 to $568.53 3-Month Outlook: Projected fall of -13.32%, reaching $495.41 by March 20, 2026, with a range of $478.43 to $510.56. 1-Year Outlook: Projected gain of 14.11%, with price at $652.16 by December 22, 2026, within a range of $631.13 to $671.62.